Artiva Biotherapeutics, which had been evaluating cell therapy AlloNK for the treatment of rheumatoid arthritis and other autoimmune diseases, is exploring strategic options that could include dissolution and liquidation.
After 2 patient deaths and cell therapy durability concerns, Artiva cuts 94% of workforce